1. Home
  2. CINGW vs HBB Comparison

CINGW vs HBB Comparison

Compare CINGW & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • HBB
  • Stock Information
  • Founded
  • CINGW N/A
  • HBB 1904
  • Country
  • CINGW United States
  • HBB United States
  • Employees
  • CINGW 13
  • HBB N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • HBB Home Furnishings
  • Sector
  • CINGW Health Care
  • HBB Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • HBB Nasdaq
  • Market Cap
  • CINGW N/A
  • HBB N/A
  • IPO Year
  • CINGW 2021
  • HBB 2017
  • Fundamental
  • Price
  • CINGW $0.07
  • HBB $30.40
  • Analyst Decision
  • CINGW
  • HBB
  • Analyst Count
  • CINGW 0
  • HBB 0
  • Target Price
  • CINGW N/A
  • HBB N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • HBB 67.1K
  • Earning Date
  • CINGW N/A
  • HBB 10-30-2024
  • Dividend Yield
  • CINGW N/A
  • HBB 1.52%
  • EPS Growth
  • CINGW N/A
  • HBB 313.35
  • EPS
  • CINGW N/A
  • HBB 2.47
  • Revenue
  • CINGW N/A
  • HBB $644,781,000.00
  • Revenue This Year
  • CINGW N/A
  • HBB $4.60
  • Revenue Next Year
  • CINGW N/A
  • HBB N/A
  • P/E Ratio
  • CINGW N/A
  • HBB $12.29
  • Revenue Growth
  • CINGW N/A
  • HBB 5.28
  • 52 Week Low
  • CINGW N/A
  • HBB $10.88
  • 52 Week High
  • CINGW N/A
  • HBB $31.05
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • HBB 59.12
  • Support Level
  • CINGW N/A
  • HBB $29.27
  • Resistance Level
  • CINGW N/A
  • HBB $31.02
  • Average True Range (ATR)
  • CINGW 0.00
  • HBB 1.21
  • MACD
  • CINGW 0.00
  • HBB -0.13
  • Stochastic Oscillator
  • CINGW 0.00
  • HBB 77.51

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: